- News Home
17 April 2014 12:48 pm ,
Vol. 344 ,
Three years ago, Jennifer Francis of Rutgers University proposed that a warming Arctic was altering the behavior of the...
Officials last week revealed that the U.S. contribution to ITER could cost $3.9 billion by 2034—roughly four times the...
An experimental hepatitis B drug that looked safe in animal trials tragically killed five of 15 patients in 1993. Now,...
Using the two high-quality genomes that exist for Neandertals and Denisovans, researchers find clues to gene activity...
A new report from the Intergovernmental Panel on Climate Change (IPCC) concludes that humanity has done little to slow...
Astronomers have discovered an Earth-sized planet in the habitable zone of a red dwarf—a star cooler than the sun—500...
- 17 April 2014 12:48 pm , Vol. 344 , #6181
- About Us
Bill Gates Makes Major AIDS Donation
3 May 1999 6:00 pm
Microsoft CEO Bill Gates and his wife Melinda will announce tomorrow a $25 million contribution to the International AIDS Vaccine Initiative (IAVI), the largest single philanthropic donation ever made to AIDS research, Science has learned. "Bill and Melinda Gates are very excited and pleased to partner with organizations making such a difference in global health," confirms Trevor Neilson, a spokesperson for the William H. Gates Foundation.
IAVI will receive $5 million a year for the next 5 years from the foundation, which last June gave the New York-based nonprofit $1.5 million. According to Neilson, $13.5 million will fund up to three new international AIDS vaccine development teams. Another $3.5 million will support the two such teams put together last year to develop HIV vaccines specifically for Kenya and South Africa. Between $2.5 million and $3.5 million will go to IAVI's applied research program, advocacy and clinical trial preparation in developing countries, and operational support. "This historic act of generosity will allow us to significantly accelerate the scientific effort," says Seth Berkley, president of IAVI.
The new donation will more double IAVI's coffers to nearly $50 million and should significantly heighten the institute's ability to carry out development and human trials of these vaccines. The National Institutes of Health still remains by far the largest player in the field, now spending $200 million a year on HIV vaccine R&D. The iconoclastic IAVI, however, hopes to approach the problem from a novel angle, marrying academics from both wealthy and poor countries with cash-strapped companies.